

CITATION REPORT

List of articles citing

Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar

DOI: 10.1007/s40259-021-00487-6
BioDrugs, 2021, 35, 459-468.

Source: <https://exaly.com/paper-pdf/80703688/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
3	Immunogenicity of Rituximab biosimilar GP2013 in chronic inflammatory rheumatic disorders in daily clinical practice.. <i>Seminars in Arthritis and Rheumatism</i> , 2022 , 52, 151951	5.3	0
2	A novel rituximab administration protocol to minimize infusion-related adverse reactions in patients with B-cell lymphoma. <i>International Journal of Clinical Pharmacy</i> , 2021 , 44, 366	2.3	0
1	Severe Hypersensitivity Reactions at Biosimilar versus Originator Rituximab Treatment Initiation, Switch and Over Time: A Cohort Study on the French National Health Data System.		0